Floatz logo

PHENYTOIN

Immunodeficiencies

Columbia UniversitySmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Immunodeficiencies cohort.

Asset / SponsorPhaseRating
Evomela
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2BB
Busulphan
University of California, San Francisco
Phase 2BB
Thiotepa
University of California, San Francisco
Phase 2BB
Fludarabine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2BB
HUMAN IMMUNOGLOBULINS
Grifols Therapeutics LLC
Phase 3B

View all 23 →

Same molecule, other indications

PHENYTOIN is also rated in:

epilepsyDormant
BB
Indicative ·
66 / 100
View asset →
traumatic brain injuryDormant
B
Indicative ·
63 / 100
View asset →
epilepsy with generalized tonic-clonic seizuresDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →